Routine annual meeting results with no earnings or guidance implications. The equity plan amendment adds modest potential dilution (~4% of shares outstanding) but is standard practice. No trading action warranted.
BMRN drugs
BMRN drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 5 $56.77entry
- T+1 · 5mo ago −0.39%α −0.61% · $56.55
- T+5 · 5mo ago −1.44%α −2.01% · $55.95
- T+20 · 4mo ago +3.56%α +1.70% · $58.79
- T+60 · 3mo ago +14.28%α +10.28% · $64.87
Price Chart
How similar events traded
Executive Summary
BioMarin filed an 8-K reporting results from its 2026 Annual Meeting of Stockholders. Shareholders approved all four proposals, including the election of ten director nominees, ratification of KPMG as auditor, an advisory vote on executive compensation, and an amendment to the 2017 Equity Incentive Plan to increase the share reserve by 7,650,000 shares. This is a routine administrative filing with no material financial impact.
Key Facts
- Shareholders approved an amendment to the 2017 Equity Incentive Plan, increasing the share reserve by 7,650,000 shares.
- All ten director nominees were elected with strong majority support.
- KPMG LLP was ratified as independent auditor for fiscal year 2026.
- Advisory vote on named executive officer compensation passed with ~87% of votes cast in favor.
- 193,270,028 shares were entitled to vote; 175,813,292 shares were present or represented at the meeting.
Financial Impact
No financial figures reported; equity plan amendment adds 7,650,000 shares to the reserve, representing approximately 3.96% of outstanding shares based on 193,270,028 shares entitled to vote.
Risk Factors
- Potential future dilution from equity awards granted under the amended plan.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-040812 |
| Document: 0001628280-26-040812-index-headers.html | 0001628280-26-040812 |
| Document: 0001628280-26-040812-index.html | 0001628280-26-040812 |
| Document: 0001628280-26-040812.txt | 0001628280-26-040812 |
Track record
16 reports on BMRN
2 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +8.91% at T+60 after the Apr 27, 2026 report. 3 of 5 went positive at some point.
Filters
- Nov 4, 202612d ago SC 13G/A Neutral 3/10 Entry $56.12 to $56.70 Now $57.99 +3.33% ▲ +1.03% −2.26% vs SPY
- Nov 2, 202614d ago 8-K Bearish 6/10 Entry $55.66 to $57.13 Now $57.99 −4.19% ▼ −2.64% −3.23% vs SPY
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $57.49 to $56.12 Now $57.99 +0.87% ▼ −2.38% +2.34% vs SPY
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $56.00 to $57.13 Now $57.99 +3.55% ▲ +2.02% +2.73% vs SPY
- Oct 6, 20265w ago 8-K Bearish 6/10 Entry $55.20 to $55.14 Now $57.99 −5.05% ▲ +0.11% −0.87% vs SPY
- Sep 15, 20268w ago 8-K Neutral 4/10 Entry $64.45 to $63.94 Now $57.99 −10.02% ▼ −0.79% −1.61% vs SPY
- Sep 14, 20269w ago 8-K Neutral 2/10 Entry $66.41 to $64.06 Now $57.99 −12.68% ▼ −3.54% −3.65% vs SPY
- Sep 1, 202610w ago 8-K Neutral 3/10 Entry $64.84 to $64.41 Now $57.99 −10.56% ▼ −0.66% −0.74% vs SPY
- Sep 1, 202610w ago Press Release Neutral 4/10 Entry $64.84 to $64.41 Now $57.99 −10.56% ▼ −0.66% −0.74% vs SPY
- Aug 31, 202611w ago 8-K Bullish 6/10 Entry $65.23 to $64.63 Now $57.99 −11.10% ▼ −0.92% −0.78% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers